Soter Bio Ends Lobbying Relationship With Tenagrity Solutions After 18 Months
核心洞察
Soter Bio LLC (搜索), a Houston-based CDMO specializing in mRNA, cell therapy, gene therapy, and plasmid DNA production, terminated its lobbying relationship with Tenagrity Solutions LLC (搜索) on July 25.
The engagement lasted roughly 18 months and carried minimal financial weight, with Tenagrity Solutions reporting zero filing amounts for its work on behalf of Soter Bio.
Soter Bio's advocacy centered on positioning itself as a critical player in domestic pharmaceutical manufacturing and biodefense, including appropriations requests for HHS funding.
Soter Bio LLC (搜索), a Houston-based contract development and manufacturing organization (CDMO) specializing in mRNA, cell therapy, gene therapy, and plasmid DNA production, has terminated its lobbying relationship with Tenagrity Solutions LLC (搜索) after roughly 18 months of advocacy work. Tenagrity Solutions filed a termination lobbying disclosure for Soter Bio LLC covering the third quarter of 2026, with the relationship formally terminated on July 25.
The engagement itself carried minimal financial weight. Tenagrity Solutions LLC (搜索) reported zero filing amounts for its lobbying work on behalf of Soter Bio LLC (搜索). For context, Tenagrity Solutions received $130,000 in lobbying fees from another client, 1Day Sooner Action Project Inc. (搜索), suggesting the Soter Bio relationship was not a major revenue contributor.
A Focus on Domestic Manufacturing and Biodefense
Soter Bio's lobbying agenda centered on positioning itself as a critical player in domestic pharmaceutical manufacturing and biodefense. The company sought to raise awareness of its capabilities among Congress, the Department of Defense, and the Department of Health and Human Services (HHS). It submitted appropriations requests for HHS funding focused specifically on domestic pharmaceutical manufacturing capacity and framed that capacity as essential for disaster preparedness.
The company also pursued a Department of Defense chemical, biological, radiological, and nuclear (CBRN) facility visit, signaling alignment with military biodefense priorities.
Broader Federal Context
The timing of this engagement reflects broader federal interest in reshoring pharmaceutical and biological manufacturing. The proposed HHS budget for fiscal year 2027 represented a 4 percent cut below the fiscal year 2026 enacted levels, potentially affecting the availability of new appropriations for manufacturing initiatives that Soter Bio was pursuing.
Caroline DeBerry, founder and CEO of Tenagrity Solutions and a lawyer with prior Hill experience as a legislative assistant in the office of former Rep. John J. Duncan Jr. (R-TN-2), served as the primary lobbyist on the engagement.